As always, a great performance. I always have to restrain myself from immediately falling into FOMO with you. That's why I'm more of a reader than a discussion participant lately.
Strong dividend performance. That always looks good. But the payout ratio is quite high, how sustainable is that? I wouldn't necessarily bet on whether US funding will normalize in the future. The restructuring of the subsidiaries also has to take effect first. I think this one is a good one to put on the watch list and then look at a few positive restructuring reports later.
Strong dividend performance. That always looks good. But the payout ratio is quite high, how sustainable is that? I wouldn't necessarily bet on whether US funding will normalize in the future. The restructuring of the subsidiaries also has to take effect first. I think this one is a good one to put on the watch list and then look at a few positive restructuring reports later.
•
11
•
@Keineui Yes, an exciting company, but one that is very dependent on research expenditure.
••
@Keineui I don't see any problems with the research budget in the long term - humanity as a whole has to keep on researching, sooner or later it will continue. But there are other reasons that speak against the company: The rise in interest rates in the UK is a headwind.
Incidentally, I would rather look at the adjusted EPS or FCF of the companies, as the normal EPS is massively contaminated by amortization of intangible assets.
Incidentally, I would rather look at the adjusted EPS or FCF of the companies, as the normal EPS is massively contaminated by amortization of intangible assets.
•
22
•